Evernow publishes distinct patch and vaginal-tablet pages alongside membership and single-visit care. Their product purpose, access period and pharmacy payment route should remain separate in a comparison.
Evernow lets prospective patients encounter estradiol through several records: a patch page, a vaginal-tablet page, a care-model comparison and a general FAQ. Each describes a different part of the service. The useful task is connecting them without turning a monthly care price into a medicine price or a product page into a personal treatment recommendation.
We reviewed these official pages on September 28, 2026. They establish a menopause care offering and named estradiol forms, but not the complete medicine a particular patient would receive. Product-specific details that the reviewed records do not establish remain open questions for the clinician and pharmacy.
Evernow has separate official records for an estradiol patch and vaginal estradiol tablets. The distinction is meaningful before considering price: the pages frame different delivery routes and treatment purposes. Neither establishes the exact manufacturer, strength or supplied quantity for a particular prescription.
The patch, tablet and gel guide helps identify the route language, while the vaginal identity guide preserves the vaginal qualifier. The reviewed product information does not provide a complete dispensing label. This review therefore does not infer an approval status, dosing schedule or universal indication for the preparation a particular patient might receive.
The how-it-works page distinguishes pay-per-visit care from membership. Pay-per-visit includes a virtual consultation and 90-day access to prescriptions and the care platform. Membership describes ongoing access, secure messaging and automated refills throughout membership. These are access terms, not a guarantee of a 90-day medicine supply or indefinite prescribing.
The Stella review provides a comparison with another virtual visit and pharmacy pathway. The relevant difference concerns how care is accessed and continued, rather than whether a longer platform-access period means a larger prescription or a clinically preferable treatment plan.
Evernow’s FAQ lists $49 for month-to-month membership, $129 for three months with a $43 monthly equivalent, and $420 for twelve months with a $35 monthly equivalent. The service’s starting-at-$35 display therefore needs its annual period beside it. It is not the price of a freely chosen one-month enrollment.
The FAQ separately gives a self-pay video-visit fee of $150. Optional video visits during membership can involve insurance copays or deductibles, or that self-pay fee. Membership fees are not insurance-covered according to the record, though HSA/FSA eligibility is described. These amounts do not establish the price of any prescribed estradiol product.
Evernow says many prescriptions can go to a preferred local or online pharmacy where insurance and applicable discounts may be used. It also says some medications must be fulfilled through partner pharmacies for cash payment. A broad statement that medications are usually covered cannot remove that product-specific exception.
The Pandia review examines another service with a pharmacy pathway distinct from clinical membership. For either provider, the label and pharmacy record guide helps connect the selected medicine to its actual dispensing source. The public pages do not establish which benefit, price or fulfillment restriction would apply to an individual prescription. The FAQ excludes Medicare and Medicaid from its supported visit coverage. That exclusion should not be lost when national commercial insurer names appear elsewhere on the same site.
The FAQ names GoGo Meds and Art of Medicine as fulfillment pharmacies and describes primarily USPS shipping in discreet packaging. Those are logistical statements about Evernow’s service. They do not identify which partner would supply every estradiol preparation or establish the product’s manufacturer, label or approval status.
A shipped parcel, a prescription transmission and a care-plan entry are separate records. This review did not inspect any of them for an actual patient. The MyMenopauseRx review is useful for comparison because it describes pharmacy-selection and transfer steps more explicitly. Neither provider’s public workflow guarantees stock, delivery timing or successful transfer of a particular order.
Evernow advertises round-the-clock secure messaging and says replies are often received within a day. The ability to send a message at any hour is different from a guaranteed clinician response time. The FAQ also describes necessary laboratory or additional medical information being requested according to the proposed care.
The medication-list guide can help keep current prescriptions and other products available for that assessment. It does not offer a laboratory interpretation or determine whether two treatments can be combined. The provider’s all-50-states-and-DC statement likewise describes service availability, while a particular clinician match and prescription decision still require the actual care process.
The patch page contains broad statements about long-term cardiovascular and cognitive support, and both product pages include patient testimonials. This review does not use those statements to promise prevention, individual relief or superiority over another route. FDA’s menopause guidance keeps benefits and risks within a personal clinical discussion rather than a shopping conclusion.
Evernow’s useful public distinctions are its separate product pages, two access models and qualified fulfillment options. The unfinished fields are the exact prescription, supplied version, medicine charge and follow-up responsibilities. Resolving those through the clinician and pharmacy is different from selecting a membership display, and no personal hormone instructions are supplied here.
Follow the source
Provider pages describe services. Medical and regulatory sources supply clinical context. None of these references substitutes for a personal assessment.